Buy, Sell or Hold: Danaher Corp. (DHR-N) — Stock Predictions at Stockchase

NYSE:DHR

291.14

5.90 (2.07%) 1d

Showing 1 to 15 of 30 entries

BUY

He recommends it, but has had a rough year. It did good business during Covid, mostly in Covid testing. But this created tough comparisons. Recently, it reported an excellent quarter. DHR reported a big top and bottom line beat and gave robust full-year and current-quarter guidance. Share have been rallying ever since. They are genuises in integrating businesses they buy. Also, 75% of their business is recurring revenues.

machinery

BUY on WEAKNESS

He;s been buying this as it's been going down. He really likes it now. DHR is in talks to make an acquisition in life sciences. Shares are pressured because of PCR testing as the street feels that Covid is going away. Has a low PE and offers good growth.

machinery

PARTIAL SELL

Likes the life sciences and diagnostics exposure here. DHR is a serial acquirer, starting to divest businesses. You can take some profits and buy Stryker.

machinery

TOP PICK

A conglomerate in the healthcare space. They have done exceedingly well during COVID. They integrated into genomic medicine. (Analysts’ price target is $340.03)

machinery

BUY

They report Thursday. They have a high-growth healthcare business that they partly picked up from GE for a song. He expects a great quarter.

machinery

DON'T BUY

A diversified industrial company in the life science and diagnostic services business. Has grown through acquisitions. Has made 2 dozens acquisitions in the past year. Bought GE's biopharma business. Relatively expensive at 40x earnings. Does not warrant this type of price tag. Nothing wrong but a little expensive for him.

machinery

COMMENT

DHR vs. TMO vs. WAT WAT not performing as well as Thermo Fisher or Danaher. Cash from operations has been flat in the last 4 years, whereas the other two have doubled, which is reflected in the stock price. Market share, operating margins, and pricing power impact the business model. Compare these when assessing competitors in an industry.

machinery

COMMENT

A fine long-term performer. They bought a biopharma asset from GE and will report on it in on Wednesday.

machinery

PAST TOP PICK

(A Top Pick Oct 28/19, Up 54%) Covid is impacting them. They bought GE pharma division, and the timing couldn't be better. Grown dividend by 28% over the last 5 years, paying down debt.

machinery

BUY

They produce consumables for drug production, a great company. For the discovery and production of drugs. They're in a unique situation, because their filtration systems also apply to industrial production.

machinery

WAIT

Has long owned this. It's benefited from COVID, because DHR prrovides testing equipment. Their latest acquisition was huge, from GE's bio-farm unit. DHR is expensive now, but this is good for the long term. Buy only half or a third now and see what happens with volatility in the fall running up the U.S. election.

machinery

WATCH

It is rather like a 3-M, a healthcare services like company, diagnostics, etc. He thinks it is a fabulous company. Maybe you want to hold this for a longer period of time. Margins may be peaking, however. In the US healthcare is tied to employment. The dividend is actually quite small. You want to focus on this in the post-COVID-19 environment.

machinery

PAST TOP PICK

(A Top Pick Jan 17/19, Up 54%) A life-sciences companies that also does consumables and mass spectrometers. They recently purchased the GE biopharma section. They have big margins coming into the company. Earnings were higher than their peer group. He has owned this since 2013 and he sees no reason to sell it. He wouldn't enter now with 30x earnings. It works as a core holding since life science has good growth potential.

machinery

COMMENT

As a roll-up It was a roll-up, but not now. The new DHR is a producer of filtration systems and single-use consumables that help make biotech drugs. They have a leading market share, supplying most major biotechs around the world. He likes it. Little is built into the numbers now and investors are very conservative about forecasting the biotech drug market.

machinery

SELL

They have been a successful franchise and acquisition story. His concern has always been valuation. This is a great company. It should be on your radar. It is too expensive so you should sell it.

machinery

Showing 1 to 15 of 30 entries

Danaher Corp.(DHR-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 2

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 3

Stockchase rating for Danaher Corp. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Danaher Corp.(DHR-N) Frequently Asked Questions

What is Danaher Corp. stock symbol?

Danaher Corp. is a American stock, trading under the symbol DHR-N on the New York Stock Exchange (DHR). It is usually referred to as NYSE:DHR or DHR-N

Is Danaher Corp. a buy or a sell?

In the last year, 3 stock analysts published opinions about DHR-N. 2 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Danaher Corp..

Is Danaher Corp. a good investment or a top pick?

Danaher Corp. was recommended as a Top Pick by on . Read the latest stock experts ratings for Danaher Corp..

Why is Danaher Corp. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Danaher Corp. worth watching?

3 stock analysts on Stockchase covered Danaher Corp. In the last year. It is a trending stock that is worth watching.

What is Danaher Corp. stock price?

On 2022-08-10, Danaher Corp. (DHR-N) stock closed at a price of $291.14.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.